Laboratory of Plasma and Processes (LPP), Technological Institute of Aeronautics (ITA), Praça Marechal Eduardo Gomes, 50, Vila das Acácias, São José dos Campos, SP 12228-900, Brazil.
J Mater Chem B. 2021 Feb 25;9(7):1745-1761. doi: 10.1039/d0tb01783c.
Cases of respiratory diseases have been increasing around the world, affecting the health and quality of life of millions of people every year. Chronic respiratory diseases (CRDs) and acute respiratory infections (ARIs) are responsible for many hospital admissions and deaths, requiring sophisticated treatments that facilitate the delivery of therapeutics to specific target sites with controlled release. In this context, different nanoparticles (NPs) have been explored to match this demand, such as lipid, liposome, protein, carbon-based, polymeric, metallic, oxide, and magnetic NPs. The use of NPs as drug delivery systems can improve the efficacy of commercial drugs due to their advantages related to sustained drug release, targeting effects, and patient compliance. The current review presents an updated summary of recent advances regarding the use of NPs as drug delivery systems to treat diseases related to the respiratory tract, such as CRDs and ARIs. The latest applications presented in the literature were considered, and the opportunities and challenges of NPs in the drug delivery field are discussed.
全球范围内,呼吸道疾病的病例一直在增加,每年影响着数百万人的健康和生活质量。慢性呼吸道疾病(CRD)和急性呼吸道感染(ARI)导致许多人住院和死亡,需要复杂的治疗方法,以便将治疗药物递送到特定的靶位,并进行控制释放。在这种情况下,已经探索了不同的纳米颗粒(NPs)来满足这一需求,例如脂质、脂质体、蛋白质、基于碳的、聚合的、金属的、氧化物和磁性 NPs。由于 NPs 具有与持续药物释放、靶向作用和患者顺应性相关的优势,因此将 NPs 用作药物递送系统可以提高商业药物的疗效。目前的综述对 NPs 作为药物递送系统在治疗与呼吸道相关的疾病(如 CRD 和 ARI)方面的最新进展进行了更新总结。考虑了文献中最新的应用,并讨论了 NPs 在药物递送领域的机遇和挑战。